Eicosanoids and adipokines in breast cancer: From molecular mechanisms to clinical considerations

Antioxidants and Redox Signaling

Volumn 18, Issue 3, 2013, Pages 323-360

  Basu, Samar ^a,b,c,d,e   Nachat Kappes, Rachida ^a,b,c   Caldefie Chézet, Florence ^a,b,c   Vasson, Marie Paule ^a,b,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INRA and University of Auvergne   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d UPPSALA UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ADIPOCYTOKINE; APICIDIN; ARACHIDONIC ACID; AROMATASE; BUTYRIC ACID; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; CYTOCHROME P450; FREE RADICAL; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; LIPOXYGENASE; MALONALDEHYDE; OXAMFLATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN H2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; THROMBOXANE; UNINDEXED DRUG;

ABDOMINAL OBESITY; ARACHIDONIC ACID METABOLISM; BIOSYNTHESIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CELL FUNCTION; CELL PROLIFERATION; DNA DAMAGE; DNA METHYLATION; ENZYME SUBSTRATE COMPLEX; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; KIDNEY FUNCTION; LIPID PEROXIDATION; NONHUMAN; OBESITY; ONCOGENE NEU; OXIDATIVE STRESS; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ADIPOKINES; ANIMALS; BREAST NEOPLASMS; CHRONIC DISEASE; EICOSANOIDS; FEMALE; FREE RADICALS; HUMANS; INFLAMMATION; OBESITY; SIGNAL TRANSDUCTION;

EID: 84870676266     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4408     Document Type: Review

References (395)

1. Ahima RS and Flier JS. Leptin. Annu Rev Physiol 62: 413-437, 2000.
2. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, and Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature 382: 250-252, 1996. (Pubitemid 26251358)
3. Allavena P, Garlanda C, Borrello MG, Sica A, and Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18: 3-10, 2008. (Pubitemid 351694444)
4. Ando S and Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol 8: 263-275, 2011.
5. Anubhuti and Arora S. Leptin and its metabolic interactions: an update. Diabetes Obes Metab 10: 973-993, 2008.
6. Arditi JD, Venihaki M, Karalis KP, and Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 39: 9-13, 2007. (Pubitemid 46535150)
7. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999. (Pubitemid 29299050)
8. Ashok V, Dash C, Rohan TE, Sprafka JM, and Terry PD. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20: 66-70, 2011.
9. Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, and DuBois RN. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 68: 9331-9337, 2008.
10. Badid N, Ahmed FZ, Merzouk H, Belbraouet S, Mokhtari N, Merzouk SA, Benhabib R, Hamzaoui D, and Narce M. Oxidant/antioxidant status, lipids and hormonal profile in overweight women with breast cancer. Pathol Oncol Res 16: 159-167, 2010.
11. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, Higgins B, Lokshin A, Troyer D, Hernandez J, Lynch S, Leach RJ, and Thompson IM. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 15: 1331-1335, 2006. (Pubitemid 44125290)
12. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, and Cerhan JR. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126: 149-155, 2011.
13. Barocas DA, Motley S, Cookson MS, Chang SS, Penson DF, Dai Q, Milne G, Roberts LJ, 2nd, Morrow J, Concepcion RS, Smith JA, Jr., and Fowke JH. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. J Urol 185: 2102-2107, 2011.
14. Basu S. Bioactive eicosanoids: role of prostaglandin F(2alpha) and F-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells 30: 383-391, 2010.
15. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 10: 1405-1434, 2008.
16. Basu S. Fatty acid oxidation and isoprostanes: oxidative strain and oxidative stress. Prostaglandins Leukot Essent Fatty Acids 82: 219-225, 2010.
17. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 38: 105-122, 2004. (Pubitemid 38181167)
18. Basu S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med Res Rev 27: 435-468, 2007. (Pubitemid 46991953)
19. Basu S and Helmersson J. [Bioactive isoprostanes. New markers of oxidative stress and inflammation-related diseases]. Lakartidningen 106: 274-278, 2009.
20. Basu S and Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 7: 221-235, 2005. (Pubitemid 40187939)
21. Basu S and Kindahl H. Development of a continuous blood collection technique and a detailed study of prostaglandin F2 alpha release during luteolysis and early pregnancy in heifers. J Vet Med A 34: 487-500, 1987.
22. Basu S, Kindahl H, Harvey D, and Betteridge KJ. Metabolites of PGF2 alpha in blood plasma and urine as parameters of PGF2 alpha release in cattle. Acta Vet Scand 28: 409-420, 1987.
23. Basu S, Miclescu A, Sharma H, and Wiklund L. Propofol mitigates systemic oxidative injury during experimental cardiopulmonary cerebral resuscitation. Prostaglandins Leukot Essent Fatty Acids 84: 123-130, 2011.
24. Basu S, Sjoquist B, Resul B, and Stjernschantz J. Presence of a 15-ketoprostaglandin delta 13-reductase in porcine cornea. Acta Chem Scand 46: 108-110, 1992.
25. Basu S and Stjernschantz J. Delta13-reductase dependent metabolism of prostaglandins in the mammalian brain and eye. Prostaglandins Leukot Essent Fatty Acids 57: 305-310, 1997. (Pubitemid 27454266)
26. Beltowski J, Wojcicka G, and Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 170: 21-29, 2003. (Pubitemid 37086705)
27. Ben-Av P, Crofford LJ, Wilder RL, and Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 372: 83-87, 1995.
28. Bhattacharyya M, Girish GV, Ghosh R, Chakraborty S, and Sinha AK. Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. Cancer Sci 101: 2105-2109, 2010.
29. Bjelakovic G, Nikolova D, Simonetti RG, and Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 364: 1219-1228, 2004. (Pubitemid 39311342)
30. Bjorbak C, Lavery HJ, Bates SH, Olson RK, Davis SM, Flier JS, and Myers MG, Jr. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 275: 40649-40657, 2000. (Pubitemid 32064706)
31. Blair CK, Sweeney C, Anderson KE, and Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101: 191-197, 2007. (Pubitemid 46115425)
32. Botha JH, Robinson KM, Ramchurren N, Reddi K, and Norman RJ. Human esophageal carcinoma cell lines: prostaglandin production, biological properties, and behavior in nude mice. J Natl Cancer Inst 76: 1053-1056, 1986. (Pubitemid 16093138)
33. Bouloumie A, Marumo T, Lafontan M, and Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 13: 1231-1238, 1999. (Pubitemid 29300368)
34. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Goerlitz DS, Trevisan M, Shields PG, and Freudenheim JL. Nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 22: 965-975, 2011.
35. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Trevisan M, Shields PG, and Freudenheim JL. Non-steroidal antiinflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21: 1503-1512, 2010.
36. Brasky TM, Bonner MR, Moysich KB, Ochs-Balcom HM, Marian C, Ambrosone CB, Nie J, Tao MH, Edge SB, Trevisan M, Shields PG, and Freudenheim JL. Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 126: 157-165, 2011.
37. Brodie A, Long B, and Lu Q. Aromatase expression in the human breast. Breast Cancer Res Treat 49 Suppl 1: S85-S91; discussion S109-S119, 1998.
38. Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, and Thijssen JH. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79: 41-47, 2001. (Pubitemid 34158777)
39. Brueggemeier RW. Update on the use of aromatase inhibitors in breast cancer. Expert Opin Pharmacother 7: 1919-1930, 2006. (Pubitemid 44489366)
40. Brueggemeier RW and Diaz-Cruz ES. Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches. Minerva Endocrinol 31: 13-26, 2006.
41. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, and Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140: 27-35, 1999. (Pubitemid 29251310)
42. Brueggemeier RW, Su B, Sugimoto Y, Diaz-Cruz ES, and Davis DD. Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol 106: 16-23, 2007. (Pubitemid 47362646)
43. Bulun SE and Simpson ER. Aromatase expression in women's cancers. Adv Exp Med Biol 630: 112-132, 2008.
44. Burks DJ, Font de Mora J, Schubert M, Withers DJ, Myers MG, Towery HH, Altamuro SL, Flint CL, and White MF. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 407: 377-382, 2000.
45. Caldefie-Chezet F, Damez M, de Latour M, Konska G, Mishellani F, Fusillier C, Guerry M, Penault-Llorca F, Guillot J, and Vasson MP. Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun 334: 737-741, 2005. (Pubitemid 41033183)
46. Calder PC and Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 56: S14-S19, 2002.
47. Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579-591, 2004. (Pubitemid 39025053)
48. Caminos JE, Nogueiras R, Gallego R, Bravo S, Tovar S, Garcia-Caballero T, Casanueva FF, and Dieguez C. Expression and regulation of adiponectin and receptor in human and rat placenta. J Clin Endocrinol Metab 90: 4276-4286, 2005. (Pubitemid 41058209)
49. Cantley LC and Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999. (Pubitemid 29190320)
50. Carulli L, Ferrari S, Bertolini M, Tagliafico E, and Del Rio G. Regulation of ob gene expression: evidence for epinephrine-induced suppression in human obesity. J Clin Endocrinol Metab 84: 3309-3312, 1999. (Pubitemid 30646960)
51. Casabiell X, Pineiro V, Peino R, Lage M, Camina J, Gallego R, Vallejo LG, Dieguez C, and Casanueva FF. Gender differences in both spontaneous and stimulated leptin secretion by human omental adipose tissue in vitro: dexamethasone and estradiol stimulate leptin release in women, but not in men. J Clin Endocrinol Metab 83: 2149-2155, 1998. (Pubitemid 28496352)
52. Casadesus G, Smith MA, Basu S, Hua J, Capobianco DE, Siedlak SL, Zhu X, and Perry G. Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener 2: 2, 2007.
53. Cascio S, Bartella V, Auriemma A, Johannes GJ, Russo A, Giordano A, and Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene 27: 540-547, 2008.
54. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, and Ando S. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278: 28668-28676, 2003. (Pubitemid 36935773)
55. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML, and Ando S. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 279: 19908-19915, 2004. (Pubitemid 38623433)
56. Ceddia RB. Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis. Int J Obes 29: 1175-1183, 2005. (Pubitemid 43080295)
57. Cernuda-Morollon E, Pineda-Molina E, Canada FJ, and Perez-Sala D. 15-Deoxy-Delta 12, 14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 276: 35530-35536, 2001.
58. Chajes V, Torres-Mejia G, Biessy C, Ortega-Olvera C, Angeles-Llerenas A, Ferrari P, Lazcano-Ponce E, and Romieu II. omega-3 and omega-6 polyunsaturated fatty acid intakes and the risk of breast cancer in Mexican women: impact of obesity status. Cancer Epidemiol Biomarkers Prev 21: 319-326, 2012.
59. Chehab FF, Lim ME, and Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12: 318-320, 1996. (Pubitemid 26080094)
60. Chen C, Chang YC, Liu CL, Chang KJ, and Guo IC. Leptininduced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat 98: 121-132, 2006. (Pubitemid 44050760)
61. Chen D, Reierstad S, Lin Z, Lu M, Brooks C, Li N, Innes J, and Bulun SE. Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts. Cancer Res 67: 8914-8922, 2007. (Pubitemid 47437469)
62. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF, and Yuan SS. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237: 109-114, 2006.
63. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, and Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495, 1996. (Pubitemid 26060722)
64. Chen JX and Stinnett A. Critical role of the NADPH oxidase subunit p47phox on vascular TLR expression and neointimal lesion formation in high-fat diet-induced obesity. Lab Invest 88: 1316-1328, 2008.
65. Chen QR, Miyaura C, Higashi S, Murakami M, Kudo I, Saito S, Hiraide T, Shibasaki Y, and Suda T. Activation of cytosolic phospholipase A2 by platelet-derived growth factor is essential for cyclooxygenase-2-dependent prostaglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1. J Biol Chem 272: 5952-5958, 1997. (Pubitemid 27102432)
66. Chen S. Aromatase and breast cancer. Front Biosci 3: d922-d933, 1998.
67. Chinen T, Komai K, Muto G, Morita R, Inoue N, Yoshida H, Sekiya T, Yoshida R, Nakamura K, Takayanagi R, and Yoshimura A. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat Commun 2: 190, 2011.
68. Chua SC, Jr., Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, and Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271: 994-996, 1996. (Pubitemid 26066874)
69. Chua SC, Jr., Liu SM, Li Q, Sun A, DeNino WF, Heymsfield SB, and Guo XE. Transgenic complementation of leptin receptor deficiency. II. Increased leptin receptor transgene dose effects on obesity/diabetes and fertility/lactation in lepr-db/db mice. Am J Physiol Endocrinol Metabol 286: E384-E392, 2004. (Pubitemid 38292688)
70. Cleary MP, Grande JP, Juneja SC, and Maihle NJ. Dietinduced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer 50: 174-180, 2004.
71. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, and Maihle NJ. Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogeneinduced mammary tumors. Exp Biol Med 229: 182-193, 2004. (Pubitemid 38146562)
72. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, Juneja SC, Grande JP, and Maihle NJ. Genetically obese MMTV-TGF-alpha/ Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 77: 205-215, 2003. (Pubitemid 36197635)
73. Cleveland RJ, Gammon MD, Long CM, Gaudet MM, Eng SM, Teitelbaum SL, Neugut AI, and Santella RM. Common genetic variations in the LEP and LEPR genes, obesity and breast cancer incidence and survival. Breast Cancer Res Treat 120: 745-752, 2010.
74. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, and Morrow JD. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94: 657-662, 1997. (Pubitemid 27053689)
75. Costa Cdos S, Rohden F, Hammes TO, Margis R, Bortolotto JW, Padoin AV, Mottin CC, and Guaragna RM. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARgamma1-3 mRNA expression in human visceral adipocytes. Obes Surg 21: 356-361, 2011.
76. Covey TM, Edes K, Coombs GS, Virshup DM, and Fitzpatrick FA. Alkylation of the tumor suppressor PTEN activates Akt and beta-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PloS One 5: e13545, 2010.
77. Covey TM, Edes K, and Fitzpatrick FA. Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 26: 5784-5792, 2007. (Pubitemid 47312821)
78. Cracowski JL, Stanke-Labesque F, and Bessard G. [Isoprostanes: new markers of oxidative stress. Fundamental and clinical aspects]. Rev Med Interne 21: 304-307, 2000.
79. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, and Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12: 496-503, 2011.
80. Dagogo-Jack S, Tykodi G, and Umamaheswaran I. Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans. J Clin Endocrinol Metab 90: 5333-5335, 2005. (Pubitemid 41262297)
81. Dai Q, Gao YT, Shu XO, Yang G, Milne G, Cai Q, Wen W, Rothman N, Cai H, Li H, Xiang Y, Chow WH, and Zheng W. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. J Clin Oncol 27: 2482-2488, 2009.
82. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, and Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2: 544-551, 2001. (Pubitemid 33586867)
83. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF, and Rabson AB. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32: 1381-1387, 2011.
84. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, and Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98: 1004-1009, 1996. (Pubitemid 26293319)
85. Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, and Brichard SM. Pre-and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 367: 677-685, 2002. (Pubitemid 35305706)
86. Dennis EA. Modification of the arachidonic acid cascade through phospholipase A2 dependent mechanisms. Adv Prostaglandin Thromboxane Leukot Res 20: 217-223, 1990.
87. Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, and Ranscht B. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res 15: 3256-3264, 2009.
88. Diers AR, Dranka BP, Ricart KC, Oh JY, Johnson MS, Zhou F, Pallero MA, Bodenstine TM, Murphy-Ullrich JE, Welch DR, and Landar A. Modulation of mammary cancer cell migration by 15-deoxy-delta(12, 14)-prostaglandin J(2): implications for anti-metastatic therapy. Biochem J 430: 69-78, 2010.
89. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, and Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 293: 622-628, 2002. (Pubitemid 34694255)
90. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, and Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998. (Pubitemid 28418937)
91. Ducsay CA, Hyatt K, Mlynarczyk M, Kaushal KM, and Myers DA. Long-term hypoxia increases leptin receptors and plasma leptin concentrations in the late-gestation ovine fetus. Am J Physiol Regul Integr Comp Physiol 291: R1406-R1413, 2006. (Pubitemid 44794219)
92. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R, and McTiernan A. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29: 32-39, 2011.
93. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, and Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88: 988-993, 1996. (Pubitemid 26239387)
94. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, and Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med 169: 115-121; discussion 121, 2009.
95. Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, Takahashi H, Nakajima N, Wada K, Takeda K, Nakagama H, and Nakajima A. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 60: 1363-1371, 2011.
96. Esposito K, Ciotola M, and Giugliano D. Mediterranean diet, endothelial function and vascular inflammatory markers. Public Health Nutr 9: 1073-1076, 2006.
97. Fasshauer M, Klein J, Neumann S, Eszlinger M, and Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290: 1084-1089, 2002. (Pubitemid 34687474)
98. Ferlay J, Parkin DM, and Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
99. Ferrario A and Gomer CJ. Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor. Methods Mol Biol 635: 121-132, 2010.
100. Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, Molino A, Parolin V, Di Stefano B, Bonetti F, Giordano A, Cetto GL, and Surmacz E. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 8: 305, 2008.
101. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 351: 1709-1711, 2004.
102. FitzGerald GA, Pedersen AK, and Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67: 1174-1177, 1983. (Pubitemid 13105335)
103. Fluhmann CF. The physiology of the estrogenic hormones. Trans Pac Coast Obstet Gynecol Soc 17: 167-171, 1949.
104. Frankenberry KA, Skinner H, Somasundar P, McFadden DW, and Vona-Davis LC. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 28: 985-993, 2006.
105. Friedewald VE, Bennett JS, Christo JP, Pool JL, Scheiman JM, Simon LS, Strand V, White WB, Williams GW, and Roberts WC. AJC editor's consensus: selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. Am J Cardiol 106: 873-884, 2010.
106. Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, and Olsen JH. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 17: 88-96, 2008. (Pubitemid 351301619)
107. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 393: 7-20, 2006. (Pubitemid 43049298)
108. Fukushima M. Biological activities and mechanisms of action of PGJ2 and related compounds: an update. Prostaglandins Leukot Essent Fatty Acids 47: 1-12, 1992.
109. Fukushima M. Prostaglandin J2-anti-tumour and antiviral activities and the mechanisms involved. Eicosanoids 3: 189-199, 1990.
110. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875, 2001. (Pubitemid 33101574)
111. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, and Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761, 2004. (Pubitemid 40385531)
112. Furuyashiki T and Narumiya S. Roles of prostaglandin E receptors in stress responses. Curr Opin Pharmacol 9: 31-38, 2009.
113. Fusco R, Galgani M, Procaccini C, Franco R, Pirozzi G, Fucci L, Laccetti P, and Matarese G. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr-Relat Cancer 17: 373-382, 2010.
114. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, and Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121: 211-215, 2007. (Pubitemid 46753870)
115. Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, and Zhao L. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci 100: 389-395, 2009.
116. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S, and Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 12: 1447-1453, 2006.
117. Garonna E, Botham KM, Birdsey GM, Randi AM, Gonzalez-Perez RR, and Wheeler-Jones CP. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PloS One 6: e18823, 2011.
118. Gaudet MM, Falk RT, Gierach GL, Lacey JV, Jr., Graubard BI, Dorgan JF, and Brinton LA. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol 34: 580-586, 2010.
119. Gautron L and Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 121: 2087-2093, 2011.
120. Geisler J and Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 11: 2809-2821, 2005. (Pubitemid 40525179)
121. Gierach GL, Lacey JV, Jr., Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, and Brinton LA. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10: R38, 2008.
122. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, and Seibert K. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 305 (Pt 2): 479-484, 1995.
123. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, and Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166: 1150-1158, 2007. (Pubitemid 350022753)
124. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, and Willett WC. Body mass index and risk of prostate cancer in U. S. health professionals. J Natl Cancer Inst 95: 1240-1244, 2003. (Pubitemid 37069555)
125. Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP, and Rueda BR. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 281: 26320-26328, 2006. (Pubitemid 44401840)
126. Granstrom E and Kindahl H. Species differences in circulating prostaglandin metabolites. Relevance for the assay of prostaglandin release. Biochim Biophys Acta 713: 555-569, 1982. (Pubitemid 13174753)
127. Granstrom E, Kindahl H, and Swahn ML. Profiles of prostaglandin metabolites in the human circulation. Identification of late-appearing, long-lived products. Biochim Biophys Acta 713: 46-60, 1982. (Pubitemid 13206454)
128. Greene ER, Huang S, Serhan CN, and Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 96: 27-36, 2011.
129. Grosfeld A, Zilberfarb V, Turban S, Andre J, Guerre-Millo M, and Issad T. Hypoxia increases leptin expression in human PAZ6 adipose cells. Diabetologia 45: 527-530, 2002. (Pubitemid 34533831)
130. Guo S and Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PloS One 6: e21467, 2011.
131. Guo S, Liu M, Wang G, Torroella-Kouri M, and Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 1825: 207-222, 2012.
132. Haegele AD, Wolfe P, and Thompson HJ. X-radiation induces 8-hydroxy-2¢-deoxyguanosine formation in vivo in rat mammary gland DNA. Carcinogenesis 19: 1319-1321, 1998. (Pubitemid 28375386)
133. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724, 1994.
134. Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J 401: 1-11, 2007. (Pubitemid 46115897)
135. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol 141: 312-322, 2006. (Pubitemid 43974521)
136. Hamberg M, Israelsson U, and Samuelsson B. Metabolism of prostaglandin E 2 in guinea pig liver. Ann N Y Acad Sci 180: 164-180, 1971.
137. Hamberg M and Samuelsson B. Detection and isolation of intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci USA 70: 899-903, 1973.
138. Hamberg M and Samuelsson B. Oxygenation of unsaturated fatty acids by the vesicular gland of sheep. J Biol Chem 242: 5344-5354, 1967.
139. Hamberg M and Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 71: 3400-3404, 1974.
140. Hamberg M, Svensson J, and Samuelsson B. Thromboxanes: a new family of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994-2998, 1974.
141. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R, Klaere S, Komnenovic V, Mimata H, Yoshimatsu H, Takahashi N, von Haeseler A, Bader M, Kilic SS, Ueta Y, Pifl C, Narumiya S, and Penninger JM. Central control of fever and female body temperature by RANKL/RANK. Nature 462: 505-509, 2009.
142. Hanaka H, Pawelzik SC, Johnsen JI, Rakonjac M, Terawaki K, Rasmuson A, Sveinbjornsson B, Schumacher MC, Hamberg M, Samuelsson B, Jakobsson PJ, Kogner P, and Radmark O. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci USA 106: 18757-18762, 2009.
143. Harris RE, Beebe-Donk J, and Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 42: 193-212, 2007.
144. Harris RE, Namboodiri K, Stellman SD, and Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 24: 119-120, 1995.
145. Harris RE, Namboodiri KK, and Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7: 203-205, 1996. (Pubitemid 26068056)
146. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, and Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 71: 1715-1720, 2007. (Pubitemid 47010924)
147. Helmersson J, Larsson A, Vessby B, and Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 181: 201-207, 2005. (Pubitemid 40812327)
148. Helmersson J, Vessby B, Larsson A, and Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 109: 1729-1734, 2004. (Pubitemid 38500674)
149. Himmetoglu S, Dincer Y, Ersoy YE, Bayraktar B, Celik V, and Akcay T. DNA oxidation and antioxidant status in breast cancer. J Investig Med 57: 720-723, 2009.
150. Hoffstedt J, Arvidsson E, Sjolin E, Wahlen K, and Arner P. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 89: 1391-1396, 2004. (Pubitemid 38368442)
151. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, and Scherer PE. Receptormediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55-63, 2011.
152. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, and Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472, 2010.
153. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, and Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56: 901-911, 2007. (Pubitemid 46525054)
154. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 9: 210, 2007.
155. Hsieh FC, Cheng G, and Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 335: 292-299, 2005. (Pubitemid 41140220)
156. Hu E, Liang P, and Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703, 1996. (Pubitemid 26145805)
157. Huang CY, Yu HS, Lai TY, Yeh YL, Su CC, Hsu HH, Tsai FJ, Tsai CH, Wu HC, and Tang CH. Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol 226: 1274-1282, 2011.
158. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, and Lodish HF. T-cadherin is a receptor for hexameric and highmolecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101: 10308-10313, 2004. (Pubitemid 38924921)
159. Ingalls AM, Dickie MM, and Snell GD. Obese, a new mutation in the house mouse. J Hered 41: 317-318, 1950.
160. Ishihara O, Hayashi M, Osawa H, Kobayashi K, Takeda S, Vessby B, and Basu S. Isoprostanes, prostaglandins and tocopherols in pre-eclampsia, normal pregnancy and nonpregnancy. Free Radic Res 38: 913-918, 2004. (Pubitemid 39341686)
161. Ishikawa M, Kitayama J, and Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10: 4325-4331, 2004. (Pubitemid 38878870)
162. Isse N, Ogawa Y, Tamura N, Masuzaki H, Mori K, Okazaki T, Satoh N, Shigemoto M, Yoshimasa Y, Nishi S, et al. Structural organization and chromosomal assignment of the human obese gene. J Biol Chem 270: 27728-27733, 1995.
163. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Yamaguchi M, Namiki S, Nakayama R, Tabata M, Ogata H, Kubota N, Takamoto I, Hayashi YK, Yamauchi N, Waki H, Fukayama M, Nishino I, Tokuyama K, Ueki K, Oike Y, Ishii S, Hirose K, Shimizu T, Touhara K, and Kadowaki T. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2 + ) and AMPK/SIRT1. Nature 464: 1313-1319, 2010.
164. Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, and Persson B. Common structural features of MAPEG-a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci 8: 689-692, 1999. (Pubitemid 29117984)
165. Jakobsson PJ, Thoren S, Morgenstern R, and Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96: 7220-7225, 1999. (Pubitemid 29299642)
166. Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, Guillot J, and Vasson MP. Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology 53: 484-487, 2008.
167. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, and Vasson MP. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr-Relat Cancer 16: 1197-1210, 2009.
168. Jarde T, Perrier S, Vasson MP, and Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 47: 33-43, 2011.
169. Jeong YJ, Bong JG, Park SH, Choi JH, and Oh HK. Expression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancer. J Breast Cancer 14: 96-103, 2011.
170. Jiang L, You J, Yu X, Gonzalez L, Yu Y, Wang Q, Yang G, Li W, Li C, and Liu Y. Tyrosine-dependent and-independent actions of leptin receptor in control of energy balance and glucose homeostasis. Proc Natl Acad Sci USA 105: 18619-18624, 2008.
171. Jockenhovel F, Blum WF, Vogel E, Englaro P, Muller-Wieland D, Reinwein D, Rascher W, and Krone W. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 82: 2510-2513, 1997. (Pubitemid 27337865)
172. Jonasson S, Hjoberg J, Hedenstierna G, and Basu S. Allergen-induced formation of F2-isoprostanes in a murine asthma model identifies oxidative stress in acute airway inflammation in vivo. Prostaglandins Leukot Essent Fatty Acids 80: 1-7, 2009.
173. Jousse C, Parry L, Lambert-Langlais S, Maurin AC, Averous J, Bruhat A, Carraro V, Tost J, Letteron P, Chen P, Jockers R, Launay JM, Mallet J, and Fafournoux P. Perinatal undernutrition affects the methylation and expression of the leptin gene in adults: implication for the understanding of metabolic syndrome. FASEB J 25: 3271-3278, 2011.
174. Kadlubar FF, Anderson KE, Haussermann S, Lang NP, Barone GW, Thompson PA, MacLeod SL, Chou MW, Mikhailova M, Plastaras J, Marnett LJ, Nair J, Velic I, and Bartsch H. Comparison of DNA adduct levels associated with oxidative stress in human pancreas. Mutat Res 405: 125-133, 1998. (Pubitemid 29042188)
175. Kansanen E, Kivela AM, and Levonen AL. Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta12, 14-prostaglandin J2. Free Radic Biol Med 47: 1310-1317, 2009.
176. Kappes A and Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 32: 548-554, 2000. (Pubitemid 32176085)
177. Karaduman M, Bilici A, Ozet A, Sengul A, Musabak U, and Alomeroglu M. Tissue leptin levels in patients with breast cancer. J BUON 15: 369-372, 2010.
178. Karihtala P, Kauppila S, Puistola U, and Jukkola-Vuorinen A. Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology 58: 854-862, 2011.
179. Kawamori T, Uchiya N, Sugimura T, and Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24: 985-990, 2003. (Pubitemid 36748916)
180. Kim EH, Na HK, Kim DH, Park SA, Kim HN, Song NY, and Surh YJ. 15-Deoxy-Delta12, 14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis 29: 688-695, 2008.
181. Kim EH and Surh YJ. 15-deoxy-Delta12, 14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors. Biochem Pharmacol 72: 1516-1528, 2006.
182. Kim EJ, Choi MR, Park H, Kim M, Hong JE, Lee JY, Chun HS, Lee KW, and Park JH. Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells, and mortality in obesity-resistant BALB/c mice. Breast Cancer Res 13: R78, 2011.
183. Kim Y, Stolarska MA, and Othmer HG. The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol 106: 353-379, 2011.
184. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, and Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166: 709-716, 2007. (Pubitemid 47347905)
185. Klaunig JE, Wang Z, Pu X, and Zhou S. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol 254: 86-99, 2011.
186. Klimcakova E, Kovacikova M, Stich V, and Langin D. Adipokines and dietary interventions in human obesity. Obes Rev 11: 446-456, 2010.
187. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, and Matsuzawa Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94: e27-e31, 2004.
188. Kobayashi T and Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 68-69: 557-573, 2002. (Pubitemid 35247420)
189. Koki AT and Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9: 28-35, 2002. (Pubitemid 34457338)
190. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, and Mantzoros CS. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92: 1041-1048, 2007. (Pubitemid 46465681)
191. Krause MP, Liu Y, Vu V, Chan L, Xu A, Riddell MC, Sweeney G, and Hawke TJ. Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and function. Am J Physiol Cell Physiol 295: C203-C212, 2008. (Pubitemid 352755800)
192. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, and Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 151: 32-42, 2010.
193. Kryston TB, Georgiev AB, Pissis P, and Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 711: 193-201, 2011.
194. Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, and Nakshatri H. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol 163: 2531-2541, 2003. (Pubitemid 37466494)
195. Kuo HW, Chou SY, Hu TW, Wu FY, and Chen DJ. Urinary 8-hydroxy-2¢- deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients. Mutat Res 631: 62-68, 2007.
196. Kuper H, Adami HO, and Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 248: 171-183, 2000. (Pubitemid 33702479)
197. Kutlu S, Canpolat S, Aydin M, Yasar A, Tuzcu M, and Baydas G. Exogenous leptin increases lipid peroxidation in the mouse brain. Tohoku J Exp Med 206: 233-236, 2005. (Pubitemid 40895027)
198. Kwan ML, Habel LA, Slattery ML, and Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18: 613-620, 2007. (Pubitemid 46883678)
199. La Guardia M, Giammanco S, Di Majo D, Tabacchi G, Tripoli E, and Giammanco M. Omega 3 fatty acids: biological activity and effects on human health. Panminerva Med 47: 245-257, 2005. (Pubitemid 43471968)
200. Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, Moon RT, Shepherd PR, Cooper GJ, and Wang Y. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PloS One 4: e4968, 2009.
201. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW, and Scherer PE. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 15: 3265-3276, 2009.
202. Lee PP and Ip MM. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukot Essent Fatty Acids 45: 21-31, 1992.
203. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997. (Pubitemid 27148818)
204. Li S, Shin HJ, Ding EL, and van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302: 179-188, 2009.
205. Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff K, and Kasid A. Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J Cell Biochem 35: 1-16, 1987. (Pubitemid 17167393)
206. Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT, and Wang Y. Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 29: 2195-2202, 2008.
207. Liu M, Zhou L, Xu A, Lam KS, Wetzel MD, Xiang R, Zhang J, Xin X, Dong LQ, and Liu F. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc Natl Acad Sci USA 105: 18302-18307, 2008.
208. Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A, Holland JF, and Levine AC. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277: 50081-50086, 2002. (Pubitemid 36014461)
209. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, and Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J 12: 57-65, 1998. (Pubitemid 28060271)
210. Longmire AW, Roberts LJ, and Morrow JD. Actions of the E2-isoprostane, 8-ISO-PGE2, on the platelet thromboxane/endoperoxide receptor in humans and rats: additional evidence for the existence of a unique isoprostane receptor. Prostaglandins 48: 247-256, 1994.
211. Lopez Fontana CM, Maselli ME, Perez Elizalde RF, Di Milta Monaco NA, Uvilla Recupero AL, and Lopez Laur JD. Leptin increases prostate cancer aggressiveness. J Physiol Biochem 67: 531-538, 2011.
212. Lou PH, Yang G, Huang L, Cui Y, Pourbahrami T, Radda GK, Li C, and Han W. Reduced body weight and increased energy expenditure in transgenic mice over-expressing soluble leptin receptor. PloS One 5: e11669, 2010.
213. Maccio A and Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal 11: 2020-2036, 2011.
214. Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, Astara G, Chessa P, and Mantovani G. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med 88: 677-686, 2010.
215. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221: 286-289, 1996. (Pubitemid 26136463)
216. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, and Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737, 2002. (Pubitemid 34778727)
217. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, and Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adiposederived protein. Diabetes 50: 2094-2099, 2001. (Pubitemid 33643677)
218. Maeda T and Horiuchi N. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. J Biochem 145: 771-781, 2009.
219. Mangiapane S, Blettner M, and Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 17: 115-124, 2008.
220. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, and Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89: 1102-1107, 2004. (Pubitemid 38368397)
221. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, and Dong LQ. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8: 516-523, 2006.
222. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575-5589, 1992.
223. Marnett LJ. Chemistry and biology of DNA damage by malondialdehyde. IARC Sci Publ 17-27, 1999.
224. Marnett LJ. Cyclooxygenase mechanisms. Curr Opin Chem Biol 4: 545-552, 2000.
225. Marnett LJ. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 181-182: 219-222, 2002. (Pubitemid 36015702)
226. Mason MM, He Y, Chen H, Quon MJ, and Reitman M. Regulation of leptin promoter function by Sp1, C/EBP, and a novel factor. Endocrinology 139: 1013-1022, 1998. (Pubitemid 28510118)
227. Matarese G, Moschos S, and Mantzoros CS. Leptin in immunology. J Immunol 174: 3137-3142, 2005. (Pubitemid 40354011)
228. Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, Giordano C, Bartella V, Casaburi I, and Ando S. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer Res 67: 3412-3421, 2007. (Pubitemid 46724882)
229. Maury E and Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314: 1-16, 2010.
230. McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DS, Aiello Bowles EJ, White E, Rossing MA, Potter J, and Urban N. No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 18: 1524-1530, 2009.
231. Meadows JW, Eis AL, Brockman DE, and Myatt L. Expression and localization of prostaglandin E synthase isoforms in human fetal membranes in term and preterm labor. J Clin Endocrinol Metab 88: 433-439, 2003. (Pubitemid 36115199)
232. Meadows JW, Pitzer B, Brockman DE, and Myatt L. Differential localization of prostaglandin E synthase isoforms in human placental cell types. Placenta 25: 259-265, 2004. (Pubitemid 38514934)
233. Mehrotra S, Morimiya A, Agarwal B, Konger R, and Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 208: 356-363, 2006. (Pubitemid 43210522)
234. Melzner I, Scott V, Dorsch K, Fischer P, Wabitsch M, Bruderlein S, Hasel C, and Moller P. Leptin gene expression in human preadipocytes is switched on by maturationinduced demethylation of distinct CpGs in its proximal promoter. J Biol Chem 277: 45420-45427, 2002. (Pubitemid 36159150)
235. Milagro FI, Campion J, Garcia-Diaz DF, Goyenechea E, Paternain L, and Martinez JA. High fat diet-induced obesity modifies the methylation pattern of leptin promoter in rats. J Physiol Biochem 65: 1-9, 2009.
236. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, and Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9: 5699-5704, 2003. (Pubitemid 37499493)
237. Moncada S and Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30: 293-331, 1978. (Pubitemid 10198932)
238. Montuschi P, Barnes P, and Roberts LJ, 2nd. Insights into oxidative stress: the isoprostanes. Curr Med Chem 14: 703-717, 2007. (Pubitemid 46477722)
239. Montuschi P, Ragazzoni E, Valente S, Corbo G, Mondino C, Ciappi G, and Ciabattoni G. Validation of 8-isoprostane and prostaglandin E(2) measurements in exhaled breath condensate. Inflamm Res 52: 502-507, 2003. (Pubitemid 38058224)
240. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, and Dannenberg AJ. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4: 1021-1029, 2011.
241. Morrow JD. Is oxidant stress a connection between obesity and atherosclerosis? Arterioscler Thromb Vasc Biol 23: 368-370, 2003. (Pubitemid 36337207)
242. Morrow JD. The isoprostanes-unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr Pharm Des 12: 895-902, 2006.
243. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32: 377-385, 2000. (Pubitemid 32001913)
244. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, and Roberts LJd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87: 9383-9387, 1990. (Pubitemid 120030630)
245. Morrow JD and Roberts LJ, 2nd. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 51: 1-9, 1996.
246. Murata T, Aritake K, Matsumoto S, Kamauchi S, Nakagawa T, Hori M, Momotani E, Urade Y, and Ozaki H. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci USA 108: 19802-19807, 2011.
247. Murata T, Lin MI, Aritake K, Matsumoto S, Narumiya S, Ozaki H, Urade Y, Hori M, and Sessa WC. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci USA 105: 20009-20014, 2008.
248. Murphy TK, Calle EE, Rodriguez C, Kahn HS, and Thun MJ. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152: 847-854, 2000.
249. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powles T, and Coombes RC. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67: 1408-1412, 1993. (Pubitemid 23172888)
250. Musarrat J, Arezina-Wilson J, and Wani AA. Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer 32A: 1209-1214, 1996. (Pubitemid 26231805)
251. Myung SJ and Kim IH. [Role of prostaglandins in colon cancer]. Korean J Gastroenterol 51: 274-279, 2008.
252. Na HK, Park JM, Lee HG, Lee H, Myung SJ, and Surh YJ. 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy. Biochem Pharmacol 82: 1352-1360, 2011.
253. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, and Kohno N. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metab: Clin Exp 54: 194-199, 2005. (Pubitemid 40174847)
254. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, and Tomita M. Isolation and characterization of GBP28, a novel gelatinbinding protein purified from human plasma. J Biochem 120: 803-812, 1996. (Pubitemid 26385421)
255. Narumiya S, Sugimoto Y, and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193-1226, 1999. (Pubitemid 29473315)
256. Newcomer JW, Selke G, Melson AK, Gross J, Vogler GP, and Dagogo-Jack S. Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. Arch Gen Psychiatry 55: 995-1000, 1998. (Pubitemid 28506841)
257. Ning K, Miller LC, Laidlaw HA, Burgess LA, Perera NM, Downes CP, Leslie NR, and Ashford ML. A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. EMBO J 25: 2377-2387, 2006. (Pubitemid 44012221)
258. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, and Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51: 2734-2741, 2002. (Pubitemid 34970926)
259. Nkhata KJ, Ray A, Schuster TF, Grossmann ME, and Cleary MP. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21: 1611-1619, 2009.
260. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, and Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 27: 31-40, 2008.
261. Ogunwobi O, Mutungi G, and Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 147: 4505-4516, 2006. (Pubitemid 44268402)
262. Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S, and Kawata S. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 16: 1252-1257, 2010.
263. Otvos L, Jr., Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, and Surmacz E. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 47: 1578-1584, 2011.
264. Ouchi N, Parker JL, Lugus JJ, and Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11: 85-97, 2011.
265. Ozbay T and Nahta R. A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Molecular Cancer Res 6: 1052-1058, 2008.
266. Pai R, Lin C, Tran T, and Tarnawski A. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun 331: 984-992, 2005. (Pubitemid 40692458)
267. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, and Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278: 9073-9085, 2003. (Pubitemid 36800387)
268. Pan W, Hsuchou H, Tu H, and Kastin AJ. Developmental changes of leptin receptors in cerebral microvessels: unexpected relation to leptin transport. Endocrinology 149: 877-885, 2008. (Pubitemid 351397924)
269. Park J, Kusminski CM, Chua SC, and Scherer PE. Leptin receptor signaling supports cancer cell metabolism through suppression of mitochondrial respiration in vivo. Am J Pathol 177: 3133-3144, 2010.
270. Parrett M, Harris R, Joarder F, Ross M, Clausen K, and Robertson F. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10: 503-507, 1997. (Pubitemid 27122013)
271. Parrett ML, Abou-Issa HM, Alshafie G, Ross MS, Harris RE, and Robertson FM. Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms. Anticancer Res 19: 5079-5085, 1999. (Pubitemid 30103327)
272. Patterson RE, Flatt SW, Newman VA, Natarajan L, Rock CL, Thomson CA, Caan BJ, Parker BA, and Pierce JP. Marine fatty acid intake is associated with breast cancer prognosis. J Nutr 141: 201-206, 2011.
273. Peake PW, Hughes JT, Shen Y, and Charlesworth JA. Glycosylation of human adiponectin affects its conformation and stability. J Mol Endocrinol 39: 45-52, 2007. (Pubitemid 47337865)
274. Perera CN, Chin HG, Duru N, and Camarillo IG. Leptinregulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. J Endocrinol 199: 221-233, 2008.
275. Pfeiler GH, Buechler C, Neumeier M, Schaffler A, Schmitz G, Ortmann O, and Treeck O. Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 19: 787-793, 2008. (Pubitemid 351330450)
276. Pham H, Eibl G, Vincenti R, Chong B, Tai HH, and Slice LW. 15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice. Mol Carcinog 47: 466-477, 2008. (Pubitemid 351822305)
277. Pineiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, Rubio J, Dieguez C, Gualillo O, Gonzalez-Juanatey JR, and Lago F. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579: 5163-5169, 2005. (Pubitemid 41318086)
278. Poyton RO, Ball KA, and Castello PR. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab 20: 332-340, 2009.
279. Purdham DM, Zou MX, Rajapurohitam V, and Karmazyn M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol 287: H2877-H2884, 2004. (Pubitemid 39557163)
280. Qiao L and Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 281: 39915-39924, 2006. (Pubitemid 46041795)
281. Qualtrough D, Kaidi A, Chell S, Jabbour HN, Williams AC, and Paraskeva C. Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. Int J Cancer 121: 734-740, 2007.
282. Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, and Meli R. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A. 1. Br J Pharmacol 137: 799-804, 2002. (Pubitemid 35404179)
283. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, and Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metabol 290: E42-E46, 2006.
284. Ray A, Nkhata KJ, and Cleary MP. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol 30: 1499-1509, 2007.
285. Ray A, Nkhata KJ, Grande JP, and Cleary MP. Diet-induced obesity and mammary tumor development in relation to estrogen receptor status. Cancer Lett 253: 291-300, 2007. (Pubitemid 47017540)
286. Ready A, Velicer CM, McTiernan A, and White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109: 533-543, 2008. (Pubitemid 351692052)
287. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, and Penichet ML. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 11: R36, 2009.
288. Research WCRFAifC. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. AICR: Washington DC, 2007.
289. Reuter S, Gupta SC, Chaturvedi MM, and Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49: 1603-1616, 2010.
290. Ricciotti E and FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31: 986-1000, 2011.
291. Richards AA, Colgrave ML, Zhang J, Webster J, Simpson F, Preston E, Wilks D, Hoehn KL, Stephenson M, Macdonald GA, Prins JB, Cooney GJ, Xu A, and Whitehead JP. Sialic acid modification of adiponectin is not required for multimerization or secretion but determines half-life in circulation. Mol Endocrinol 24: 229-239, 2010.
292. Rieusset J, Auwerx J, and Vidal H. Regulation of gene expression by activation of the peroxisome proliferatoractivated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265: 265-271, 1999.
293. Rigas B, Goldman IS, and Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523, 1993. (Pubitemid 23352474)
294. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, and Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002. (Pubitemid 34126931)
295. Rodriguez-Pacheco F, Martinez-Fuentes AJ, Tovar S, Pinilla L, Tena-Sempere M, Dieguez C, Castano JP, and Malagon MM. Regulation of pituitary cell function by adiponectin. Endocrinology 148: 401-410, 2007. (Pubitemid
296. Rose DP and Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83: 217-244, 1999. (Pubitemid 29430123)
297. Rose DP, Connolly JM, Rayburn J, and Coleman M. Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J Natl Cancer Inst 87: 587-592, 1995.
298. Rossner P, Jr., Gammon MD, Terry MB, Agrawal M, Zhang FF, Teitelbaum SL, Eng SM, Gaudet MM, Neugut AI, and Santella RM. Relationship between urinary 15-F2tisoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15: 639-644, 2006.
299. Roszkowski K, Jozwicki W, Blaszczyk P, Mucha-Malecka A, and Siomek A. Oxidative damage DNA: 8-oxoGua and 8-oxodG as molecular markers of cancer. Med Sci Monit 17: CR329-CR333, 2011.
300. Ruhl CE and Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 74: 295-301, 2001. (Pubitemid 32802013)
301. Saad MF, Damani S, Gingerich RL, Riad-Gabriel MG, Khan A, Boyadjian R, Jinagouda SD, el-Tawil K, Rude RK, and Kamdar V. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 82: 579-584, 1997. (Pubitemid 27068633)
302. Sales KJ, Boddy SC, and Jabbour HN. F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene 27: 2466-2477, 2008. (Pubitemid 351521090)
303. Samuelsson B. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Biosci Rep 3: 791-813, 1983. (Pubitemid 14239220)
304. Samuelsson B. Prostaglandins, thromboxanes, and leukotrienes: formation and biological roles. Harvey Lect 75: 1-40, 1979.
305. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, and Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 47: 997-1029, 1978.
306. Samuelsson B, Granstrom E, Green K, Hamberg M, and Hammarstrom S. Prostaglandins. Annu Rev Biochem 44: 669-695, 1975.
307. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, and Sharma D. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 68: 9712-9722, 2008.
308. Scherer PE, Williams S, Fogliano M, Baldini G, and Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749, 1995.
309. Schreinemachers DM and Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146, 1994. (Pubitemid 24073387)
310. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, Gutzki FM, Berger J, Frolich JC, and Boger RH. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched casecontrol study. Circulation 109: 843-848, 2004. (Pubitemid 38252735)
311. Serhan CN, Arita M, Hong S, and Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 39: 1125-1132, 2004. (Pubitemid 40129055)
312. Shapiro L and Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8: 335-338, 1998. (Pubitemid 28159119)
313. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, and Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 8: R71, 2006.
314. Sheng H, Shao J, Washington MK, and DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081, 2001.
315. Shenton KC, Dowsett M, Lu Q, Brodie A, Sasano H, Sacks NP, and Rowlands MG. Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas. Breast Cancer Res Treat 49 Suppl 1: S101-S107; discussion S109-S119, 1998.
316. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, and Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11: 1096-1103, 2005. (Pubitemid 41486832)
317. Shin MJ, Lee JH, Jang Y, Park E, Oh J, Chung JH, and Chung N. Insulin resistance, adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: leptin as an 8-epi-prostaglandin F2alpha determinant. Metab: Clin Exp 55: 918-922, 2006. (Pubitemid 44183818)
318. Shin MJ and Park E. Plasma levels of leptin are associated with the plasma levels of LDL conjugated dienes in children. Ann Nutr Metab 51: 1-6, 2007. (Pubitemid 46633183)
319. Shin SW, Seo CY, Han H, Han JY, Jeong JS, Kwak JY, and Park JI. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res 15: 5414-5425, 2009.
320. Shyu KG, Chen SC, Wang BW, Cheng WP, and Hung HF. Mechanism of inhibitory effect of atorvastatin on leptin expression induced by angiotensin II in cultured human coronary artery smooth muscle cells. Clin Sci 122: 33-42, 2012.
321. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, and Flores-Riveros JR. Biological action of leptin as an angiogenic factor. Science 281: 1683-1686, 1998. (Pubitemid 28435586)
322. Sies H. (Ed). Oxidative Stress: Introductory Remarks. London: Academic Press, 1985, p. 1-8.
323. Simmons DL. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 110: 265-268, 2003. (Pubitemid 37329823)
324. Simmons DL, Botting RM, and Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387-437, 2004. (Pubitemid 39096597)
325. Simmons DL, Botting RM, Robertson PM, Madsen ML, and Vane JR. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci USA 96: 3275-3280, 1999. (Pubitemid 29148881)
326. Simmons DL, Chandrasekharan NV, Hu D, Roos KL, and Tomsik J. Comments on "acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties". J Pharmacol Exp Ther 315: 1412-1414; author reply 1415-1416, 2005.
327. Simmons DL, Levy DB, Yannoni Y, and Erikson RL. Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA 86: 1178-1182, 1989. (Pubitemid 19061517)
328. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, and Jones M. Aromatase-a brief overview. Annu Rev Physiol 64: 93-127, 2002.
329. Sinaiko AR, Steinberger J, Moran A, Prineas RJ, Vessby B, Basu S, Tracy R, and Jacobs DR, Jr. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation 111: 1985-1991, 2005. (Pubitemid 40570219)
330. Singh P, Hoffmann M, Wolk R, Shamsuzzaman AS, and Somers VK. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 27: e302-e307, 2007. (Pubitemid 47312298)
331. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
332. Smith PM and Ferguson AV. Neurophysiology of hunger and satiety. Dev Disabil Res Rev 14: 96-104, 2008.
333. Smith WL, DeWitt DL, and Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
334. Smith WL, Garavito RM, and DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 271: 33157-33160, 1996.
335. Sodergren E, Vessby B, and Basu S. Radioimmunological measurement of F(2)-isoprostanes after hydrolysis of lipids in tissues. Prostaglandins Leukot Essent Fatty Acids 63: 149-152, 2000.
336. Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, and Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 149: 9-14, 2008.
337. Song H, Lim H, Paria BC, Matsumoto H, Swift LL, Morrow J, Bonventre JV, and Dey SK. Cytosolic phospholipase A2alpha is crucial [correction of A2alpha deficiency is crucial] for "on-time" embryo implantation that directs subsequent development. Development 129: 2879-2889, 2002. (Pubitemid 34874267)
338. Song HC, Roux P, and Kuperman WA. Focal translation by frequency shift in free space. IEEE Trans Ultrason Ferroelectr Freq Control 47: 687-695, 2000.
339. Speert H. Mode of action of estrogens on the mammary gland. Science 92: 461-462, 1940.
340. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, and Glass CK. 15-deoxydelta 12, 14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 97: 4844-4849, 2000. (Pubitemid 30238645)
341. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, and Dannenberg AJ. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 4: 329-346, 2011.
342. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, and Dannenberg AJ. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66: 5504-5511, 2006. (Pubitemid 43844979)
343. Subbaramaiah K, Hudis C, Chang SH, Hla T, and Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 283: 3433-3444, 2008.
344. Subbaramaiah K, Norton L, Gerald W, and Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277: 18649-18657, 2002. (Pubitemid 34952420)
345. Surh YJ, Na HK, Park JM, Lee HN, Kim W, Yoon IS, and Kim DD. 15-Deoxy-Delta(12, 14)-prostaglandin J(2), an electrophilic lipid mediator of anti-inflammatory and proresolving signaling. Biochem Pharmacol 2011.
346. Szego CM and Roberts S. The nature of circulating estrogen. Proc Soc Exp Biol Med 61: 161-164, 1946.
347. Tai HH, Tong M, and Ding Y. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat 83: 203-208, 2007. (Pubitemid 46661259)
348. Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, Shimomura I, Hotta K, Kuriyama H, Kihara S, Nakamura T, Yamashita S, Funahashi T, and Matsuzawa Y. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24: 861-868, 2000. (Pubitemid 30449921)
349. Takkouche B, Regueira-Mendez C, and Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100: 1439-1447, 2008.
350. Tamiji J and Crawford DA. Prostaglandin E(2) and misoprostol induce neurite retraction in Neuro-2a cells. Biochem Biophys Res Commun 398: 450-456, 2010.
351. Tartaglia LA. The leptin receptor. J Biol Chem 272: 6093-6096, 1997. (Pubitemid 27118072)
352. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, and Tepper RI. Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271, 1995. (Pubitemid 26007816)
353. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221-5225, 1997. (Pubitemid 27516352)
354. Thorat MA, Morimiya A, Mehrotra S, Konger R, and Badve SS. Prostanoid receptor EP1 expression in breast cancer. Mod Pathol 21: 15-21, 2008.
355. Tong M, Ding Y, and Tai HH. Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem Pharmacol 72: 701-709, 2006. (Pubitemid 44233546)
356. Toomey DP, Murphy JF, and Conlon KC. COX-2, VEGF and tumour angiogenesis. Surgeon 7: 174-180, 2009.
357. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, and Hankinson SE. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 92: 1510-1516, 2007. (Pubitemid 46556432)
358. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, and Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18: 305-314, 1999. (Pubitemid 29060606)
359. Valsecchi ME, Pomerantz SC, Jaslow R, and Tester W. Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clin Breast Cancer 9: 225-230, 2009.
360. van der Donk WA, Tsai AL, and Kulmacz RJ. The cyclooxygenase reaction mechanism. Biochemistry 41: 15451-15458, 2002. (Pubitemid 36062450)
361. Van der Ouderaa FJ, Buytenhek M, Nugteren DH, and Van Dorp DA. Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta 487: 315-331, 1977. (Pubitemid 8091076)
362. Vane JR, Bunting S, and Moncada S. Prostacyclin in physiology and pathophysiology. Int Rev Exp Pathol 23: 161-207, 1982. (Pubitemid 12119863)
363. Wabitsch M, Jensen PB, Blum WF, Christoffersen CT, Englaro P, Heinze E, Rascher W, Teller W, Tornqvist H, and Hauner H. Insulin and cortisol promote leptin production in cultured human fat cells. Diabetes 45: 1435-1438, 1996. (Pubitemid 26332910)
364. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, and Kadowaki T. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278: 40352-40363, 2003. (Pubitemid 37248604)
365. Wang A, Liu M, Liu X, Dong LQ, Glickman RD, Slaga TJ, Zhou Z, and Liu F. Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMPactivated protein kinase signaling pathways and DsbA-L. J Biol Chem 286: 60-66, 2011.
366. Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F, and Dong LQ. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem 284: 31608-31615, 2009.
367. Wang D and Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31: 64-73, 2004. (Pubitemid 38543941)
368. Wang D and Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 10: 181-193, 2010.
369. Wang D and Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788, 2010.
370. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, and DuBois RN. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295, 2004. (Pubitemid 39222041)
371. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, and Xu A. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66: 11462-11470, 2006. (Pubitemid 46009979)
372. Wang Y, Lam KS, and Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res 17: 280-282, 2007. (Pubitemid 46639924)
373. Wernli KJ, Hampton JM, Trentham-Dietz A, and Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 20: 131-137, 2011.
374. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, and Koeffler HP. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66: 7818-7823, 2006. (Pubitemid 44289243)
375. Wolfle D. Enhancement of carcinogen-induced malignant cell transformation by prostaglandin F(2 alpha). Toxicology 188: 139-147, 2003. (Pubitemid 36588896)
376. World Cancer Research Fund/American Institute for Cancer Research. Food N, Physical activity, and the Prevention of Cancer: A Global Perspective. Washington DC: AICR, 2007.
377. Wu B, Fukuo K, Suzuki K, Yoshino G, and Kazumi T. Relationships of systemic oxidative stress to body fat distribution, adipokines and inflammatory markers in healthy middle-aged women. Endocr J 56: 773-782, 2009.
378. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, and Santella RM. Urinary 15-F2tisoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis 29: 971-976, 2008. (Pubitemid 351982242)
379. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, Rody A, Greb RR, Bocker W, and Kiesel L. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382, 2003. (Pubitemid 36995136)
380. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, and Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276: 25096-25100, 2001.
381. Yamakawa-Karakida N, Sugita K, Inukai T, Goi K, Nakamura M, Uno K, Sato H, Kagami K, Barker N, and Nakazawa S. Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by downregulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ 9: 513-526, 2002. (Pubitemid 34521179)
382. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769, 2003. (Pubitemid 36735700)
383. Yi P, Sun X, Doerge DR, and Fu PP. An improved 32Ppostlabeling/high- performance liquid chromatography method for the analysis of the malondialdehye-derived 1, N2-propanodeoxyguanosine DNA adduct in animal and human tissues. Chem Res Toxicol 11: 1032-1041, 1998. (Pubitemid 28447292)
384. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, and Dannenberg AJ. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7: 3971-3976, 2001. (Pubitemid 34044615)
385. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, Bidlingmaier M, Wu Z, Ajami A, Weetman AP, Strasburger CJ, and Ross RJ. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 167: 4593-4599, 2001. (Pubitemid 32954339)
386. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Clawson DK, DiMarchi RD, Furman TC, Hale JE, Hsiung HM, Schoner BE, Smith DP, Zhang XY, Wery JP, and Schevitz RW. Crystal structure of the obese protein leptin-E100. Nature 387: 206-209, 1997. (Pubitemid 27209439)
387. Zhang SM, Cook NR, Manson JE, Lee IM, and Buring JE. Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98: 989-991, 2008. (Pubitemid 351341601)
388. Zhang Y, Coogan PF, Palmer JR, Strom BL, and Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 162: 165-170, 2005. (Pubitemid 41373542)
389. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, and Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994. (Pubitemid 24365442)
390. Zhao AZ, Shinohara MM, Huang D, Shimizu M, Eldar-Finkelman H, Krebs EG, Beavo JA, and Bornfeldt KE. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J Biol Chem 275: 11348-11354, 2000. (Pubitemid 30212785)
391. Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, Hursting SD, Berger NA, and Reizes O. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr-Relat Cancer 18: 491-503, 2011.
392. Zhong H, Willard M, and Simons J. NS398 reduces hypoxiainducible factor (HIF)-1alpha and HIF-1 activity: multiplelevel effects involving cyclooxygenase-2 dependent and independent mechanisms. Int J Cancer 112: 585-595, 2004. (Pubitemid 39425938)
393. Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, Moriya T, Simpson ER, Sasano H, and Clyne CD. Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res 65: 657-663, 2005.
394. Zhou L, Liu M, Zhang J, Chen H, Dong LQ, and Liu F. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulation. Diabetes 59: 2809-2816, 2010.
395. Zhou W, Guo S, and Gonzalez-Perez RR. Leptin proangiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer 104: 128-137, 2011.